Literature DB >> 23681847

Cdc20 turnover rate: a key determinant in cancer patient response to anti-mitotic therapies?

Andrew M Fry1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23681847     DOI： 10.1002/bies.201300053

Source DB:  PubMed          Journal:  Bioessays        ISSN： 0265-9247            Impact factor:   4.345


× No keyword cloud information.
  3 in total

1.  CDC20 maintains tumor initiating cells.

Authors:  Qi Xie; Qiulian Wu; Stephen C Mack; Kailin Yang; Leo Kim; Christopher G Hubert; William A Flavahan; Chengwei Chu; Shideng Bao; Jeremy N Rich
Journal:  Oncotarget       Date:  2015-05-30

2.  Global gene expression analysis of canine cutaneous mast cell tumor: could molecular profiling be useful for subtype classification and prognostication?

Authors:  Mery Giantin; Anna Granato; Chiara Baratto; Laura Marconato; Marta Vascellari; Emanuela M Morello; Antonella Vercelli; Franco Mutinelli; Mauro Dacasto
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

3.  Drug repositioning discovery for early- and late-stage non-small-cell lung cancer.

Authors:  Chien-Hung Huang; Peter Mu-Hsin Chang; Yong-Jie Lin; Cheng-Hsu Wang; Chi-Ying F Huang; Ka-Lok Ng
Journal:  Biomed Res Int       Date:  2014-08-18       Impact factor: 3.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.